MR spectroscopy of the liver: Principles and clinical applications

Radiographics

Volumn 29, Issue 6, 2009, Pages 1653-1664

  Qayyum, Aliya ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ALGORITHM; ARTICLE; COMPUTER ASSISTED DIAGNOSIS; LIVER; LIVER DISEASE; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

ALGORITHMS; BIOLOGICAL MARKERS; DIAGNOSIS, COMPUTER-ASSISTED; LIVER; LIVER DISEASES; MAGNETIC RESONANCE SPECTROSCOPY;

EID: 77449160046     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.296095520     Document Type: Article

References (57)

1. Ross BD, Colletti P, Lin A. MR spectroscopy of the brain: neurospectroscopy. In: Edelman RR, Hesselink JR, Zlatkin MB, Crues JV, eds. Clinical magnetic resonance imaging. 3rd ed. Philadelphia, Pa: Saunders-Elsevier, 2006; 1840-1910.
2. Pagani E, Bizzi A, Di Salle F, De Stefano N, Filippi M. Basic concepts of advanced MRI technique. Neurol Sci 2008;29:290-295.
3. Leach MO. Magnetic resonance spectroscopy (MRS) in the investigation of cancer at The Royal Marsden Hospital and The Institute of Cancer Research. Phys Med Biol 2006;51:R61-R82.
4. Danielsen ER, Ross BD. Magnetic resonance spectroscopy diagnosis of neurological diseases. New York, NY: Marcel Dekker, 1999.
5. Frahm J, Bruhn H, Gyngell ML. Localized high resolution proton NMR spectroscopy using stimulated echoes: initial applications to human brain in vivo. Magn Reson Med 1989;9:79-93.
6. Mullins PG, Chen H, Xu J, Caprihan A, Gasparovic C. Comparative reliability of proton spectroscopy techniques designed to improve detection of Jcoupled metabolites. Magn Reson Med 2008;60: 964-969.
7. Mueller-Lisse UG, Scherr MK. Proton MR spectroscopy of the prostate. Eur J Radiol 2007;63:351-360.
8. Guiu B, Petit JM, Loffroy R, et al. Quantification of liver fat content: comparison of triple echo-echo chemical shift gradient-echo imaging and in vivo proton MR spectroscopy. Radiology 2009;250:95-102.
9. Michaelis T, Merboldt KD, Bruhn H, Hänicke W, Frahm J. Absolute concentrations of metabolites in the adult human brain in vivo: quantification of localized proton MR spectra. Radiology 1993;187: 219-227.
10. 1H magnetic resonance spectroscopy in the liver: a review. Liver Int 2008;28:297-307.
11. 1Hmagnetic resonance spectroscopy and a gallery of artifacts. NMR Biomed 2004;17:361-381.
12. 1H liver spectroscopy with 32-element coil arrays [abstr]. In: Proceedings of the 13th Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 2005; 1929.
13. 1H MR spectroscopy of the brain: absolute quantification of metabolites. Radiology 2006;240:318-332.
14. Thomsen C, Becker U, Winkler K, Christoffersen P, Jensen M, Henriksen O. Quantification of liver fat using magnetic resonance spectroscopy. Magn Reson Imaging 1994;12:487-495.
15. 1HMRS: analysis and correction by retro-gating. NMR Biomed 1998;11:107-114.
16. Noworolski SM, Tien PC, Merriman R, Vigneron DB, Qayyum A. Respiratory motion-corrected proton magnetic resonance spectroscopy of the liver. Magn Reson Imaging 2009;27:570-576.
17. Schwarz AJ, Leach MO. Implications of respiratory motion for the quantification of 2D MR spectroscopic imaging data in the abdomen. Phys Med Biol 2000;45:2105-2116.
18. Katz-Brull R, Rofsky NM, Lenkinski RE. Breathhold abdominal and thoracic proton MR spectroscopy at 3T. Magn Reson Med 2003;50:461-467.
19. Zhu G, Gheorghiu D, Allen PS. Motional degradation of metabolite signal strengths when using STEAM: a correction method. NMR Biomed 1992; 5:209-211.
20. 1H magnetic resonance spectroscopy. Magn Reson Med 2000;43:325-330.
21. Gabr RE, Sathyanarayana S, Schar M, Weiss RG, Bottomley PA. On restoring motion-induced signal loss in single-voxel magnetic resonance spectra. Magn Reson Med 2006;56:754-760.
22. Cowin GJ, Jonsson JR, Bauer JD, et al. Magnetic resonance imaging and spectroscopy for monitoring liver steatosis. J Magn Reson Imaging 2008;28: 937-945.
23. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438.
24. Festi D, Colecchia A, Sacco T, Bondi M, Roda E, Marchesini G. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev 2004;5:27-42.
25. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231.
26. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population based cohort study. Gastroenterology 2005;129:113-121.
27. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003;37:1202-1219.
28. Miller CM, Gondolesi GE, Florman S, et al. One hundred nine living donor transplants in adults and children: a single-center experience. Ann Surg 2001;234:301-311.
29. Ristig M, Drechsler H, Powderly WG. Hepatic steatosis and HIV infection. AIDS Patient Care STDs 2005;19:356-365.
30. Burke A, Lucey MR. Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation. Am J Transplant 2004;4: 686-693.
31. Limanond P, Raman SS, Lassman C, et al. Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings. Radiology 2004;230:276-280.
32. Negro F. Mechanisms and significance of liver steatosis in hepatitis C virus infection. World J Gastroenterol 2006;12:6756-6765.
33. Cho JY, Suh KS, Kwon CH, Yi NJ, Lee KU. Mild hepatic steatosis is not a major risk factor for hepatectomy and regenerative power is not impaired. Surgery 2006;139:508-515.
34. Nikeghbalian S, Nejatollahi SM, Salahi H, et al. Does donor's fatty liver change impact on early mortality and outcome of liver transplantation? Transplant Proc 2007;39:1181-1183.
35. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001;21:3-16.
36. Crowley H, Lewis WD, Gordon F, Jenkins R, Khettry U. Steatosis in donor and transplant liver biopsies. Hum Pathol 2000;31:1209-1213.
37. Perez-Daga JA, Santoyo J, Suarez MA, et al. Influence of degree of hepatic steatosis on graft function and postoperative complications of liver transplantation. Transplant Proc 2006;38:2468-2470.
38. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001;344:495-500.
39. Qayyum A, Chen DM, Breiman RS, et al. Evaluation of diffuse liver steatosis by ultrasound, CT, and MR imaging: which modality is best? Clin Imaging 2009;33:110-115.
40. Thomas EL, Hamilton G, Patel N, et al. Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut 2005;54: 122-127.
41. Longo R, Pollesello P, Ricci C, et al. Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J Magn Reson Imaging 1995;5:281-285.
42. Anderwald C, Bernroider E, Krssak M, et al. Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle. Diabetes 2002;51:3025-3032.
43. 1H MR spectros- copy. Radiology 2005;236:609-614.
44. 31P MR spectroscopy to histology in chronic hepatitis C. Hepatology 2003;37:788-794.
45. Cho SG, Kim MY, Kim HJ, et al. Chronic hepatitis: in vivo proton MR spectroscopic evaluation of the liver and correlation with histopathologic findings. Radiology 2001;221:740-746.
46. 31P MR spectroscopy in assessment of response to antiviral therapy for hepatitis C virus-related liver disease. AJR Am J Roentgenol 2007;189:819-823.
47. 31P signal. Magn Reson Med 1989;12:145-150.
48. 31P nuclear magnetic resonance spectroscopic investigation of human neuroblastoma in situ. N Engl J Med 1985;312:1500-1505.
49. Podo F. Tumour phospholipid metabolism. NMR Biomed 1999;12:413-439.
50. Soper R, Himmelreich U, Painter D, et al. Pathology of hepatocellular carcinoma and its precursors using proton magnetic resonance spectroscopy and a statistical classification strategy. Pathology 2002;34: 417-422.
51. Li CW, Kuo YC, Chen CY, et al. Quantification of choline compounds in human hepatic tumors by proton MR spectroscopy at 3 T. Magn Reson Med 2005;53:770-776.
52. 1H magnetic resonance spectroscopy in evaluation of hepatocellular carcinoma and its early response to transcatheter arterial chemoembolization. Chin Med Sci J 2006;21:258-264.
53. Kuo YT, Li CW, Chen CY, Jao J, Wu D, Liu GC. In vivo proton magnetic resonance spectroscopy of large focal hepatic lesions and metabolite change of hepatocellular carcinoma before and after transcatheter arterial chemoembolization using a 3.0 T MR scanner. J Magn Reson Imaging 2004;19:598-604.
54. 1H-MR spectra in vivo at 1.5 T. Magn Reson Med 2002;47:809-811.
55. Khan SA, Cox IJ, Thillainayagam AV, Bansi DS, Thomas HC, Taylor-Robinson SD. Proton and phosphorus-31 nuclear magnetic resonance spectroscopy of human bile in hepatopancreaticobiliary cancer. Eur J Gastroenterol Hepatol 2005;17:733-738.
56. 13C MR spectroscopy. J Nucl Med 2008;49:341-344.
57. Costello LC, Franklin RB. 'Why do tumour cells glycolyse?': from glycolysis through citrate to lipogenesis. Mol Cell Biochem 2005;280:1-8.